Salarius Pharmaceuticals effects 1-for-8 reverse stock split to regain Nasdaq compliance

Decoy Therapeutics Inc.

Reverse split effective 5:00 p.m. ET on June 14, 2024; trading on split-adjusted basis begins June 17.
Shares outstanding reduced from ~4.7 million to ~0.6 million; new CUSIP 79400X404.
Fractional shares paid in cash based on closing price on effective date; ticker SLRX unchanged.
Split intended to meet Nasdaq $1.00 minimum bid price requirement; stockholders had approved ratio range 1:4 to 1:8.
Authorized shares and par value unaffected; options and warrants adjusted proportionally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.